165 related articles for article (PubMed ID: 29082495)
1. High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.
Hua Y; Camarco DP; Strock CJ; Johnston PA
Methods Mol Biol; 2018; 1683():211-227. PubMed ID: 29082495
[TBL] [Abstract][Full Text] [Related]
2. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Hua Y; Shun TY; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
[TBL] [Abstract][Full Text] [Related]
3. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
4. Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2016 Oct; 14(8):453-477. PubMed ID: 27606620
[TBL] [Abstract][Full Text] [Related]
5. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.
Fancher AT; Hua Y; Close DA; Xu W; McDermott LA; Strock CJ; Santiago U; Camacho CJ; Johnston PA
SLAS Discov; 2023 Aug; ():. PubMed ID: 37549772
[TBL] [Abstract][Full Text] [Related]
6. High content screening biosensor assay to identify disruptors of p53-hDM2 protein-protein interactions.
Hua Y; Strock CJ; Johnston PA
Methods Mol Biol; 2015; 1278():555-65. PubMed ID: 25859976
[TBL] [Abstract][Full Text] [Related]
7. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
8. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor.
Song LN; Gelmann EP
J Biol Chem; 2005 Nov; 280(45):37853-67. PubMed ID: 16141201
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
[TBL] [Abstract][Full Text] [Related]
10. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
Fancher AT; Hua Y; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
[TBL] [Abstract][Full Text] [Related]
11. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
[TBL] [Abstract][Full Text] [Related]
12. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
[TBL] [Abstract][Full Text] [Related]
13. Quantitative detection of the ligand-dependent interaction between the androgen receptor and the co-activator, Tif2, in live cells using two color, two photon fluorescence cross-correlation spectroscopy.
Rosales T; Georget V; Malide D; Smirnov A; Xu J; Combs C; Knutson JR; Nicolas JC; Royer CA
Eur Biophys J; 2007 Feb; 36(2):153-61. PubMed ID: 17021805
[TBL] [Abstract][Full Text] [Related]
14. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
[TBL] [Abstract][Full Text] [Related]
15. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
[TBL] [Abstract][Full Text] [Related]
16. Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice.
Ye X; Han SJ; Tsai SY; DeMayo FJ; Xu J; Tsai MJ; O'Malley BW
Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9487-92. PubMed ID: 15983373
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.
Izumi K; Zheng Y; Li Y; Zaengle J; Miyamoto H
Int J Oncol; 2012 Nov; 41(5):1587-92. PubMed ID: 22922989
[TBL] [Abstract][Full Text] [Related]
18. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
19. Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Dudgeon DD; Shinde SN; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
Assay Drug Dev Technol; 2010 Aug; 8(4):437-58. PubMed ID: 20662736
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
